Penumbra's thrombectomy growth and new products show promise, but high valuation at 7x 2025 revenue tempers appeal for GARP ...
There will be more work involved, more filings and fees for the client, making it harder to achieve a result and diminishing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback